Sangamo Announces AAV Capsid Data

Uncategorized

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 3, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results.